Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-Augmented Conditioning for Allo-HCT in AML/MDS
NCT07214064Phase 2Not yet recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University Hospital Tübingen. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07214064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214064.